Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Shanghai Stock Exchange  >  Shanghai Pharmaceuticals Holding Co., Ltd    601607   CNE000000C82

SHANGHAI PHARMACEUTICALS HOLDING CO., LT

(601607)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Shanghai Pharmaceuticals : GRANT OF SHARE OPTIONS UNDER THE SHARE OPTION SCHEME

share with twitter share with LinkedIn share with facebook
share via e-mail
12/19/2019 | 05:36am EDT

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上海醫藥集團股份有限公司

Shanghai Pharmaceuticals Holding Co., Ltd.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock code:02607)

GRANT OF SHARE OPTIONS UNDER THE SHARE OPTION SCHEME

This announcement is made by Shanghai Pharmaceuticals Holding Co., Ltd. (the "Company") pursuant to Rule 17.06A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules").

We refer to (i) the announcement of the Company dated 30 September 2019 in relation to the proposed adoption of the Share Option Scheme and the grant thereunder, (ii) the circular of the Company dated 1 November 2019 (the "Circular") in relation to the Share Option Scheme; and (iii) the poll results announcement of the Company dated 19 December 2019. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

GRANT OF SHARE OPTIONS UNDER THE SHARE OPTION SCHEME

The Board hereby announces that the conditions of the grant of the Share Options under the Share Option Scheme have been fulfilled. On 19 December 2019, the Board (including the Independent Non-executive Directors) has approved the grant of an aggregate of 25,680,000 Share Options to 211 Participants pursuant to the authorization by the Shareholders at the EGM. Directors who are proposed to be the Participants, i.e. Mr. CHO Man, Mr. LI Yongzhong and Mr. SHEN Bo, have abstained from voting when the Board reviews and approves the grant of the Share Options. Details of the Share Options granted are set out as follows.

Date of Grant:

Exercise Price:

Number of Share Options granted:

Closing price of A Shares on the Date of

19 December 2019

RMB18.41 per A Share

25,680,000 Share Options to 211 Participants under the Share Option Scheme

RMB18.08 per A Share

1

Grant:

Validity period of the Share Options:

The Validity Period of the Share Options granted under the Share Option Scheme commences from the registration date of the grant, which shall not exceed 60 months.

The distribution details of the Share Options of the Participant are set out as follows.

Number of the

Percentage to

Percentage to total

total number

issued share capital of

Share Options

Name

Position(s)

of the Share

the Company as of the

granted

Options

date of the grant of the

('0,000 A Shares)

granted (%)

Share Options (%)

CHO Man

Executive Director,

48.00

1.69%

0.017%

President

LI Yongzhong

Executive Director,

39.00

1.37%

0.014%

Vice President

Executive Director, Vice

SHEN Bo

president, chief financial

39.00

1.37%

0.014%

officer

ZHAO Yong

Vice President

33.00

1.16%

0.012%

MAO Jianyi

Vice President

33.00

1.16%

0.012%

GU Haoliang

Vice President

33.00

1.16%

0.012%

LIU Dawei

Vice President

33.00

1.16%

0.012%

ZHANG Yaohua

Vice President

33.00

1.16%

0.012%

CHEN Jinzhu

Secretary to the Board,

33.00

1.16%

0.012%

Joint Company Secretary

Middle level management and core

employees of the Company (202 persons in

2,244.00

78.96%

0.790%

total)

Reserved Shares

274.09

9.64%

0.096%

Total

2,84.09

100.00%

1.000%

By order of the Board

Shanghai Pharmaceuticals Holding Co., Ltd.*

ZHOU Jun

Chairman

2

Shanghai, the PRC, 20 December 2019

As at the date of this announcement, the executive Directors are Mr. CHO Man, Mr. LI Yongzhong and Mr. SHEN Bo; the non-executive Directors are Mr. ZHOU Jun, Mr. GE Dawei and Ms. LI An; and the independent non-executive Directors are Mr. CAI Jiangnan, Mr. HONG Liang, Mr. GU Zhaoyang and Mr. Manson FOK.

*For identification purpose only

3

Disclaimer

Shanghai Pharmaceuticals Holding Co. Ltd. published this content on 19 December 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 December 2019 10:35:01 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SHANGHAI PHARMACEUTICALS H
01/22ENZYMATICA PUBL : signs agreement with Keyuan Trade for China
AQ
2019SHANGHAI PHARMACEUTICALS : Grant of share options under the share option scheme
PU
2019SHANGHAI PHARMACEUTICALS : Results of the extraordinary general meeting, a share..
PU
2019SHANGHAI PHARMACEUTICALS : Notification Letter and Change Request Form to Regist..
PU
2019SHANGHAI PHARMACEUTICALS : Reply slip for holders of h share attending the 2019 ..
PU
2019SHANGHAI PHARMACEUTICALS : Form of proxy of holders of h shares for use at the 2..
PU
2019SHANGHAI PHARMACEUTICALS : Proxy form of the independent non-executive director ..
PU
2019SHANGHAI PHARMACEUTICALS : Notice of 2019 second h share class meeting
PU
2019SHANGHAI PHARMACEUTICALS : Reply slip for holders of h share attending the 2019 ..
PU
2019SHANGHAI PHARMACEUTICALS : Proxy form of holders of h shares for use at the 2019..
PU
More news
Financials (CNY)
Sales 2020 205 B
EBIT 2020 6 833 M
Net income 2020 4 590 M
Debt 2020 20 938 M
Yield 2020 2,63%
P/E ratio 2020 11,6x
P/E ratio 2021 10,3x
EV / Sales2020 0,33x
EV / Sales2021 0,28x
Capitalization 47 245 M
Chart SHANGHAI PHARMACEUTICALS HOLDING CO., LTD
Duration : Period :
Shanghai Pharmaceuticals Holding Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHANGHAI PHARMACEUTICALS H
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 20,66  CNY
Last Close Price 18,74  CNY
Spread / Highest target 40,3%
Spread / Average Target 10,2%
Spread / Lowest Target -29,7%
EPS Revisions
Managers
NameTitle
Da Wei Liu Deputy Chief Executive Officer
Man Cho President & Executive Director
Jun Zhou Chairman
Bo Shen Chief Financial Officer, Executive Director & VP
Keng Xin Member-Supervisory Board
Sector and Competitors